Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint_老虎社区_美港股上老虎

Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint

Tiger Newspress2021-10-28

Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint.

The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival.

"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue," said Rafael Chief Executive Sanjeev Luther.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

112

来人
·2021-10-29
Oh no.... Buy the dip?
回复
1
举报
beanbun
·2021-10-28
wow
回复
2
举报
SFern
·2021-10-28
Good
回复
2
举报
收起
- SFern:
  Lol
  2021-10-28
  回复
  举报
Pluto891
·2021-10-28
danger of investing in pharmaceutical firm if did not get license
回复
1
举报
收起
- Jazim:
  agree
  2021-10-29
  回复
  举报
CIG
·2021-10-28
四字缺一血本无归
回复
4
举报
收起
- Galaxy121678:
  👍
  2021-10-28
  回复
  举报
Jncy
·2021-10-28
Pls like
回复
3
举报
收起
- xKira:
  Liked!
  2021-10-28
  回复
  举报
MyMelody
·2021-10-28
Like pls
回复
4
举报
收起
- ALLOYHUAT:
  Ok
  2021-10-28
  回复
  举报
- Jncy:
  Done
  2021-10-28
  回复
  举报
audreyhutah
·2021-10-28
Like
回复
4
举报
Nana_seven
·2021-10-28
Like pls o
回复
5
举报
收起
- audreyhutah:
  Ok
  2021-10-28
  回复
  举报
TSL1121
·2021-10-28
hi
回复
5
举报
收起
- TSL1121:
  hi
  2021-10-28
  回复
  举报
PeiLing_Val
·2021-10-28
Like
回复
4
举报
WhaleAlert
·2021-10-28
Ok
回复
3
举报
JiaocyTi
·2021-10-28
666
回复
4
举报
收起
- JiaocyTi:
  Great
  2021-10-28
  回复
  举报
Brugelion
·2021-10-28
Huat ar! Buy the dip!
回复
1
举报
HeroSmurf
·2021-10-28
:(
回复
1
举报
ShinChan89
·2021-10-28
Hi
回复
2
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1153909226?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-28 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153909226","market":"us","top_or_hot":-1,"title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","media":"Tiger Newspress","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n2021-10-28 21:33 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RFL","symbol_name":"Rafael Holdings, Inc.","start_time":0,"source_url":null,"article_id":"1153909226","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","pubTimestamp":1635428011,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"translate_title":"在癌症治疗试验未达到主要终点后，拉斐尔控股公司股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RFL":0.9},"content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":854210496,"gmtCreate":1635462170626,"gmtModify":1635462171114,"author":{"id":"3575544575320394","authorId":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Oh no.... Buy the&nbsp;dip?&nbsp;","listText":"Oh no.... Buy the&nbsp;dip?&nbsp;","text":"Oh no.... Buy the dip?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854210496","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854825581,"gmtCreate":1635434581314,"gmtModify":1635434581403,"author":{"id":"4094793078288150","authorId":"4094793078288150","name":"beanbun","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854825581","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854898918,"gmtCreate":1635431404699,"gmtModify":1635431404884,"author":{"id":"3582938826092533","authorId":"3582938826092533","name":"SFern","avatar":"https://static.tigerbbs.com/81a61c88544234a53cc63054a8f769b1","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854898918","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6360429,"gmtCreate":1635431414485,"gmtModify":1635431414512,"authorId":3582938826092533,"author":{"id":3582938826092533,"authorId":3582938826092533,"name":"SFern","avatar":"https://static.tigerbbs.com/81a61c88544234a53cc63054a8f769b1","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854898918,"type":1,"supId":0,"prevId":0,"content":"Lol","text":"Lol","html":"Lol"}],"langContent":"CN"},{"id":854805283,"gmtCreate":1635431070788,"gmtModify":1635431072299,"author":{"id":"3581937910767045","authorId":"3581937910767045","name":"Pluto891","avatar":"https://static.tigerbbs.com/c9963f2ef3d3ad2aff28340461d3d6d0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"danger of investing&nbsp;in pharmaceutical firm if did not get license","listText":"danger of investing&nbsp;in pharmaceutical firm if did not get license","text":"danger of investing in pharmaceutical firm if did not get license","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854805283","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6363288,"gmtCreate":1635462789510,"gmtModify":1635462789613,"authorId":4091925166419540,"author":{"id":4091925166419540,"authorId":4091925166419540,"name":"Jazim","avatar":"https://static.tigerbbs.com/85de7ecb80758afc3288fc8bb7e5ef27","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854805283,"type":1,"supId":0,"prevId":0,"content":"agree","text":"agree","html":"agree"}],"langContent":"CN"},{"id":854146580,"gmtCreate":1635430008040,"gmtModify":1635430134230,"author":{"id":"3583974841960176","authorId":"3583974841960176","name":"CIG","avatar":"https://static.tigerbbs.com/6c2077e2370e1ffcaca7e29b875be2be","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"四字缺一 血本无归&nbsp;","listText":"四字缺一 血本无归&nbsp;","text":"四字缺一 血本无归","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854146580","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6360155,"gmtCreate":1635430225989,"gmtModify":1635430226092,"authorId":4087215268151120,"author":{"id":4087215268151120,"authorId":4087215268151120,"name":"Galaxy121678","avatar":"https://static.tigerbbs.com/b0cab941d047dcba4893f77a2987c5c6","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854146580,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"CN"},{"id":854156844,"gmtCreate":1635429461642,"gmtModify":1635429764889,"author":{"id":"3584074223056401","authorId":"3584074223056401","name":"Jncy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854156844","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6360044,"gmtCreate":1635429717911,"gmtModify":1635429718008,"authorId":3581982860658315,"author":{"id":3581982860658315,"authorId":3581982860658315,"name":"xKira","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854156844,"type":1,"supId":0,"prevId":0,"content":"Liked!","text":"Liked!","html":"Liked!"}],"langContent":"CN"},{"id":854125725,"gmtCreate":1635429120851,"gmtModify":1635429183777,"author":{"id":"4097904547274900","authorId":"4097904547274900","name":"MyMelody","avatar":"https://static.tigerbbs.com/d6cd6a7b09f47978b230dcda643836b8","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/854125725","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6360113,"gmtCreate":1635430009068,"gmtModify":1635430009183,"authorId":3573364000575272,"author":{"id":3573364000575272,"authorId":3573364000575272,"name":"ALLOYHUAT","avatar":"https://static.tigerbbs.com/1ed93fe58b3eb7ac6c44343e09bfabcd","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854125725,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6359977,"gmtCreate":1635429415837,"gmtModify":1635429415938,"authorId":3584074223056401,"author":{"id":3584074223056401,"authorId":3584074223056401,"name":"Jncy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854125725,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"},{"id":854167572,"gmtCreate":1635428782619,"gmtModify":1635428783569,"author":{"id":"3581922885116926","authorId":"3581922885116926","name":"audreyhutah","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854167572","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854165160,"gmtCreate":1635428693520,"gmtModify":1635428693890,"author":{"id":"3575673754947065","authorId":"3575673754947065","name":"Nana_seven","avatar":"https://static.tigerbbs.com/cbfa864cf0a3b766b4090b0ad3b67e69","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like pls o&nbsp;","listText":"Like pls o&nbsp;","text":"Like pls o","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854165160","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6359806,"gmtCreate":1635428793789,"gmtModify":1635428793904,"authorId":3581922885116926,"author":{"id":3581922885116926,"authorId":3581922885116926,"name":"audreyhutah","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854165160,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":854166366,"gmtCreate":1635428611942,"gmtModify":1635428656276,"author":{"id":"3573295662822598","authorId":"3573295662822598","name":"TSL1121","avatar":"https://static.tigerbbs.com/b7db19d94c5608f927773028279719d2","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854166366","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6359760,"gmtCreate":1635428620861,"gmtModify":1635428620889,"authorId":3573295662822598,"author":{"id":3573295662822598,"authorId":3573295662822598,"name":"TSL1121","avatar":"https://static.tigerbbs.com/b7db19d94c5608f927773028279719d2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854166366,"type":1,"supId":0,"prevId":0,"content":"<u>hi</u>","text":"<u>hi</u>","html":"<u>hi</u>"}],"langContent":"CN"},{"id":854168775,"gmtCreate":1635428601651,"gmtModify":1635428602043,"author":{"id":"3576835207750345","authorId":"3576835207750345","name":"PeiLing_Val","avatar":"https://static.tigerbbs.com/2b9811eea8b6682a917378f2b5138a22","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854168775","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854163546,"gmtCreate":1635428532838,"gmtModify":1635428533085,"author":{"id":"4090503240947790","authorId":"4090503240947790","name":"WhaleAlert","avatar":"https://static.tigerbbs.com/75eb73613295f7b7aebfaec84aa91d1c","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854163546","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854187641,"gmtCreate":1635428405283,"gmtModify":1635428506717,"author":{"id":"3581742924827239","authorId":"3581742924827239","name":"JiaocyTi","avatar":"https://static.tigerbbs.com/c16d760078e396b46033bc97afede0c8","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854187641","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6359716,"gmtCreate":1635428464968,"gmtModify":1635428464995,"authorId":3581742924827239,"author":{"id":3581742924827239,"authorId":3581742924827239,"name":"JiaocyTi","avatar":"https://static.tigerbbs.com/c16d760078e396b46033bc97afede0c8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":854187641,"type":1,"supId":0,"prevId":0,"content":"Great<br>","text":"Great<br>","html":"Great<br>"}],"langContent":"CN"},{"id":854187814,"gmtCreate":1635428404119,"gmtModify":1635428506378,"author":{"id":"3582276661346153","authorId":"3582276661346153","name":"Brugelion","avatar":"https://static.tigerbbs.com/54098bd61c6b611c9e10125198ccdda0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Huat ar! Buy the dip!","listText":"Huat ar! Buy the dip!","text":"Huat ar! Buy the dip!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854187814","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854187976,"gmtCreate":1635428375826,"gmtModify":1635428505079,"author":{"id":"3585642689958579","authorId":"3585642689958579","name":"HeroSmurf","avatar":"https://static.tigerbbs.com/6015b234d96461c6ef8db8d919ac3473","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":":(","listText":":(","text":":(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854187976","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":854184078,"gmtCreate":1635428336239,"gmtModify":1635428489583,"author":{"id":"3581763751831637","authorId":"3581763751831637","name":"ShinChan89","avatar":"https://static.tigerbbs.com/93838fdb97783c72aa29aef28ea94143","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854184078","repostId":1153909226,"repostType":4,"repost":{"id":"1153909226","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635428011,"share":"https://www.laohu8.com/m/news/1153909226?lang=&edition=full","pubTime":"2021-10-28 21:33","market":"us","language":"en","title":"Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1153909226","media":"Tiger Newspress","summary":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the develope","content":"<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings stock plummets after cancer-treatment trial missed primary endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-28 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Rafael Holdings Inc. <a href=\"https://laohu8.com/S/RFL\">$(RFL)$</a> plummeted 78% in morning trading Thursday,&nbsp;after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. </p>\n<p><img src=\"https://static.tigerbbs.com/0208843fbf8264bc77269e3fd7a5cba5\" tg-width=\"885\" tg-height=\"630\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. </p>\n<p>\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RFL":"Rafael Holdings, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153909226","content_text":"Shares of Rafael Holdings Inc. $(RFL)$ plummeted 78% in morning trading Thursday, after the developer of cancer treatments said a Phase 3 trial of CPI-613 (devimistat) in patients with relapsed or refractory acute myeloid leukemia failed to meet its primary endpoint. \n\nThe company said devimistat, given with Folfirinox (mFFX), a current standard of care chemotherapy regimen, did not significantly improve overall survival. \n\"While we are disappointed by the outcomes of these well-designed and well-executed studies, we remain committed to furthering our research and development in cancer metabolism for the treatment of hard-to-treat cancers, as our other studies continue,\" said Rafael Chief Executive Sanjeev Luther.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":112,"commentSize":16,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}